Paxlovid, evidence base?
May 4, 2022
445,291
11,563
2,635
3.19%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Dr John Campbell Episodes Around May 4, 2022
See what was published immediately before and after this episode.
21:18Now PlayingPaxlovid, evidence base?
YouTube Description
as posted by the channelPaxlovid, it this an evidence based intervention in May 2022?
Paper FDA EMU was based on
EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients)
1120 patients received nirmatrelvir plus ritonavir
1126 received placebo
Relative risk reduction
Risk of progression to severe Covid-19, 89% lower than the risk with placebo
Absolute risk reduction
7% down to 1%
symptomatic, unvaccinated, non hospitalized adults
at high risk for progression to severe coronavirus disease 2019
July 16 and December 9, 2021
If vaccinated people and previously infected people are partly protected
More people would need to be treated to prevent one adverse event
Pfizer press release (5th November 2021)
our oral antiviral candidate, … has the potential to save patients’ lives,
reduce the severity of COVID-19 infections,
and eliminate up to nine out of ten hospitalizations
Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant
The results showed in all cases that nirmatrelvir was a potent inhibitor of its target.
PAXLOVID™ for Post-Exposure Prophylactic Use
Evaluated data from 2,957 adults
Pfizer observed risk reductions of 32% (5 day course)
37% reduction (10 day course)
These results, however, were not statistically significant and, as such, the primary endpoint of reducing the risk of confirmed and symptomatic COVID-19 infection in adults who had been exposed to the virus through a household contact was not met.
FACT SHEET FOR PATIENTS, PARENTS, AND CAREGIVERS
EMERGENCY USE AUTHORIZATION (EUA) OF PAXLOVID FOR CORONAVIRUS DISEASE 2019 (COVID-19)
PAXLOVID is not an FDA-approved medicine in the United States.
PAXLOVID is an investigational medicine
Some medicines may interact with PAXLOVID and may cause serious side effects.
If you take too much PAXLOVID, call your healthcare provider or go to the nearest hospital emergency room right away.
Possible side effects of PAXLOVID are:
Allergic Reactions
trouble swallowing or breathing, swelling of the mouth, lips, or face, throat tightness, hoarseness, skin rash
Liver Problems. Tell your healthcare provider right away,
loss of appetite, yellowing of your skin and the whites of eyes (jaundice), dark-colored urine, pale colored stools and itchy skin, stomach area (abdominal) pain.
Other possible side effects include:
altered sense of taste, diarrhea, high blood pressure, muscle aches
Dr. Ashish K. Jha, White House, Covid-19 coordinator
The new White House Covid czar says avoiding all virus infections isn’t the goal of U.S. pandemic policy.
Paxlovid, push to reach the vulnerable
Doctors are too hesitant to prescribe the drug
Senior Advisor at Albright Stonebridge Group
The firm advises clients on international policy and global markets
Patrick Vallance
From 2012 to 2018, he was President of Research and Development at global pharmaceutical company, GlaxoSmithKline (GSK)
Cashed £5,000,000 GSK shares
Future jobs of FDA’s haematology-oncology reviewers
More than a quarter of the Food and Drug Administration employees
(who approved cancer and hematology drugs from 2001 through 2010)
left the agency and now work or consult for pharmaceutical companies,
Links & Promotions
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.